Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPG302 in Schizophrenia
NCT06442462Phase 2Active, not recruiting
- Sponsor
- Spinogenix
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing SPG302 Arm with Placebo Arm (2 arms). Primary endpoints: Positive and Negative Symptoms Scale at 6 weeks, Electroencephalogram analysis at 6 weeks and 1 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
tazbentetol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06442462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442462.